Showing results (351-360 of 415) with videos related to

Sort By:
Pageof 42
Leukemia & Lymphoma|February 21, 2024
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOPRonald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
Blood|February 28, 2019
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T Jordan, Deborah A Forst, et al.
Journal of Hematology & Oncology|January 14, 2026
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphomaLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.
Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.
The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2026
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard TherapyLara Stepan, Sahar Ansari, Jeremy S Abramson, et al.
Blood|December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaJeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Blood|July 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell TherapyLeon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, et al.
Pageof 42